OnCusp Therapeutics Welcomes Dr. Dimitry Nuyten as Chief Medical Officer

On June 23, 2025, OnCusp Therapeutics, Inc., a pioneering biopharmaceutical company in clinical development, announced the appointment of Dr. Dimitry S.A. Nuyten as their Chief Medical Officer (CMO). This esteemed company is known for transforming groundbreaking preclinical research into validated therapies aimed at providing effective treatments for cancer patients. With over 17 years in oncology drug development, Dr. Nuyten's appointment is a significant milestone for OnCusp as they focus on advancing their lead program, CUSP06.

Dr. Nuyten is recognized for his extensive experience leading clinical programs globally, from initial human trials to securing regulatory approval. Under his stewardship, OnCusp aims to strategically advance CUSP06, an antibody-drug conjugate (ADC) targeting Cadherin-6 (CDH6). Dr. Nuyten will directly report to Dr. Bing Yuan, the company’s Chief Executive Officer, further enhancing the leadership team’s expertise.

Dr. Yuan expressed enthusiasm about Dr. Nuyten's addition, highlighting his impressive track record in both biotechnology and larger pharmaceutical organizations. “His expertise in advancing innovative therapies, particularly in areas involving ADCs and immuno-oncology agents, is vital as we push CUSP06 through clinical development,” he stated.

Prior to joining OnCusp, Dr. Nuyten served as CMO at Arcus Biosciences, where he led extensive clinical development initiatives, particularly in gastrointestinal, pancreatic, and renal cancers. His leadership facilitated pivotal clinical programs, and he was instrumental in co-chairing the Joint Development Committee for Arcus’ collaboration with Gilead. His experience also includes key roles at Nektar Therapeutics and Aduro Biotech, and prior to that, he was a Vice President at Pfizer. Notably, he was responsible for the registrational trials of Bavencio® (avelumab), which targeted various tumor types.

Education-wise, Dr. Nuyten earned his medical degree from the University of Groningen and completed his Ph.D. in cancer biology at the University of Amsterdam in the Netherlands. He is board-certified in radiation oncology and boasts a robust portfolio of over 30 peer-reviewed publications in the field of oncology and translational medicine.

Dr. Nuyten expressed excitement about joining OnCusp, stating, “The initial clinical data for CUSP06 are compelling, particularly in heavily pretreated patients suffering from platinum-resistant high-grade serous ovarian cancer, even without CDH6 biomarker selection. I look forward to collaborating with the team to further advance this promising program and continue delivering transformative therapeutics to patients.”

CUSP06 is currently in the Phase 1b stage of clinical trials and targets patients with platinum-resistant ovarian cancer and other advanced solid tumors. The data thus far has indicated promising efficacy, especially in patients with advanced forms of high-grade serous ovarian cancer. This ADC comprises a proprietary antibody with significant CDH6 binding affinity, complemented by a unique exatecan payload. The innovative construction of CUSP06 enables an effective combination of stability and homogeneous delivery of treatment, promising to overcome many issues related to chemoresistance often seen with current therapies.

OnCusp secured exclusive global rights for the development and commercialization of CUSP06 from Multitude Therapeutics in 2022, further showcasing its commitment to advancing cancer treatments. Since then, they have successfully raised over $100 million in Series A financing, reflecting strong investor interest led by entities such as Novo Holdings and OrbiMed.

Located in Princeton, New Jersey, OnCusp Therapeutics remains focused on their mission to transform clinical outcomes through innovation. For ongoing updates on the pivotal CUSP06 trial (NCT06234423), please visit ClinicalTrials.gov.

In summary, with Dr. Nuyten at the helm of clinical development, OnCusp Therapeutics is poised for substantial advancements in the realm of oncology, bearing hope for patients in need of innovative cancer therapies.